Skip to content
Open access

Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 47 references
Medicine

TL;DR

Elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation, and further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade is supported.

Abstract

Introduction Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear. Methods SYK expression and clinical relevance were assessed across multiple breast cancer cohorts, including radiotherapy-treated datasets. Integrated transcriptomic analyses were used to characterize SYK-associated immune states. The functional effects of pharmacologic SYK inhibition were evaluated using in vitro assays and an immunocompetent bilateral 4T1 tumor model in female BALB/c mice treated with radiotherapy and PD-1 blockade. Treatment-associated immune remodeling was assessed by flow cytometry and transcriptomic profiling. Results Across multiple cohorts, elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation. Pharmacologic SYK inhibition enhanced tumor responses to radiotherapy and PD-1 blockade at both irradiated and distant tumor sites. These effects were accompanied by coordinated remodeling of the tumor immune microenvironment, including suppression of neutrophil-associated signatures and reductions in immunosuppressive myeloid populations, including M2-like macrophages and myeloid-derived suppressor cells. Discussion Pharmacologic SYK inhibition enhances responses to radiotherapy and PD-1 blockade in preclinical TNBC models and is accompanied by remodeling of the immunosuppressive myeloid compartment. These findings support further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade.

Read PDF

Similar papers

Open access Sep 2026

RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses

The results suggest that RAMP3 contributed to the establishment of an immunosuppressive TME and integration with human clinical datasets supports further investigation of RAMP3 as a potential therapeutic target for overcoming resistance to immune checkpoint therapy in breast cancer.

Yan Zhang, Megumu Tanaka, Takayuki Sakurai et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Open access Sep 2026

63 Th17 Signature Predicts Response to Dual Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Abstract Background Combination immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 antibodies improves outcomes in metastatic renal cell carcinoma (mRCC), yet 40–60% of patients fail to achieve meaningful responses. Robust biomarkers that predict deep and durable responses are lacking. We aimed to define syste...

S. Guglietta, A. Bärenwaldt, Anthony Sonrel et al. · 0 citations
Sep 2026

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...

I. Pellicciotta, G. Manji, A. Raufi et al. · 0 citations
Open access Oct 2026

FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models

Immune checkpoint blockade (ICB) has demonstrated limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC). The fibroblast growth factor receptor (FGFR) signaling pathway contributes to tumor immune evasion, yet its role in CRC remains insufficiently understood. We investigated the immunomodulatory effec...

Zhou Shang, Chang-Qing Jing, Ji-Yuan Liu et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.